Rejuva is preclinical and has yet to be assessed by regulatory agencies.
Figures adapted from: 1. Chen et al. Mol Metab. 2017 6:943-957. 2. Biondi et al. Int J Mol Sci. 2022 23:5522
AAV-delivered glucagon-like peptide 1 receptor agonist (GLP1RA) gene therapy
Leverage our proprietary system to enable local, low dose virus delivery directly to pancreas
Vectors with high transduction efficiency and limited systemic biodistribution
Durable alteration of metabolic hormone response in the islets with tissue-restricted transgenes
Liou, et.al. presented at World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, Universal City, CA, Dec 2023
View Presentation
Rajagopalan, et al. presented at European Association for the Study of Diabetes (EASD) 2023, Hamburg, German, October 2023
View Presentation
Rajagopalan, et al. presented at American Diabetes Association 2023, San Diego, CA, June 2023
View Presentation
Rajagopalan, et al. presented at American Society of Gene and Cell Therapy, Los Angeles, CA, May 2023
View Presentation
Rajagopalan, et al. presented at American Society of Gene and Cell Therapy, Los Angeles, CA, May 2023
View Presentation
Liou, et al. presented at World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC), Universal City, CA, Dec 2022
View Presentation
Sacks, et al. presented poster at American Heart Association Meeting (AHA). Anaheim, Calif., USA, November 2017.
View Poster